Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Remi Adelaiye, Eric Ciamporcero, Kiersten Marie Miles, Paula Sotomayor, Jonathan Bard, Maria Tsompana, Dylan Conroy, Li Shen, Swathi Ramakrishnan, Sheng Yu Ku, Ashley Orillion, Joshua Prey, Gerald Fetterly, Michael Buck, Sreenivasulu Chintala, Georg A. Bjarnasone, Roberto Pili

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance may be transient and could be overcome by dose increase. In selected patients initially treated with 50 mg sunitinib and presenting with minimal toxicities, sunitinib dose was escalated to 62.5 mg and/or 75 mg at the time of tumor progression. Mice bearing two different patient-derived ccRCC xenografts (PDX) were treated 5 days per week with a dose-escalation schema (40-60-80 mg/kg sunitinib). Tumor tissues were collected before dose increments for immunohistochemistry analyses and drug levels. Selected intrapatient sunitinib dose escalation was safe and several patients had added progression-free survival. In parallel, our preclinical results showed that PDXs, although initially responsive to sunitinib at 40 mg/kg, eventually developed resistance. When the dose was incrementally increased, again we observed tumor response to sunitinib. A resistant phenotype was associated with transient increase of tumor vasculature despite intratumor sunitinib accumulation at higher dose. In addition, we observed associated changes in the expression of the methyltransferase EZH2 and histone marks at the time of resistance. Furthermore, specific EZH2 inhibition resulted in increased in vitro antitumor effect of sunitinib. Overall, our results suggest that initial sunitinib-induced resistance may be overcome, in part, by increasing the dose, and highlight the potential role of epigenetic changes associated with sunitinib resistance that can represent new targets for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)513-522
Number of pages10
JournalMolecular cancer therapeutics
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications'. Together they form a unique fingerprint.

  • Cite this

    Adelaiye, R., Ciamporcero, E., Miles, K. M., Sotomayor, P., Bard, J., Tsompana, M., Conroy, D., Shen, L., Ramakrishnan, S., Ku, S. Y., Orillion, A., Prey, J., Fetterly, G., Buck, M., Chintala, S., Bjarnasone, G. A., & Pili, R. (2015). Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular cancer therapeutics, 14(2), 513-522. https://doi.org/10.1158/1535-7163.MCT-14-0208